Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, have unveiled a strategic collaboration designed to accelerate proteomics innovation for immuno-oncology and other targeted therapies.
The partnership brings together two complementary strengths: Leinco’s extensive portfolio of high-quality antibodies—validated for critical applications such as immunohistochemistry (IHC) and advanced spatial biology platforms—and CellCarta’s catalogue of CPTAC antibodies used in its Immuno-MRM assays.
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research.
At the core of the collaboration are CellCarta’s Immuno-MRM assays, which enable highly multiplexed, quantitative protein measurements in clinical samples. Built on antibodies validated to CPTAC consortium standards, these assays allow researchers to precisely measure protein expression and function across a wide range of study settings, from early discovery to clinical trials.
By combining Leinco’s validated antibodies with CellCarta’s Immuno-MRM platform, the companies are targeting a leap forward in the sensitivity and specificity of proteomic analysis—key factors in advancing targeted therapies and personalized medicine.
"The combination of our rigorously validated antibodies—especially those proven for complex spatial analysis and IHC—with CellCarta’s robust Immuno-MRM resources creates a truly powerful and scalable solution for our customers," said Patrick Leinert Jr, President of Commercial Operations at Leinco Technologies.
"This strategic pairing is designed to provide confidence in data quality that is absolutely essential for accelerating drug development and biomarker discovery in all therapeutic areas."
The collaboration also emphasizes scalability across the research-to-clinic pipeline. CellCarta’s antibody library will be made more widely accessible through Leinco, supporting both small-scale exploratory studies and large-volume clinical applications.
"By providing our immuno-mrm antibody library to Leinco, CellCarta hopes to make these validated antibodies more widely available to researchers using broad clinical research technologies," said Todd Chermak, Senior Vice President, Immunology & Proteomics Business Units at CellCarta.
From pilot research to routine clinical testing, the combined offering is designed to support seamless transition across development stages, ensuring consistency and reproducibility at scale.
